Evaluation of the Aerosol Characteristics of an HFA Fluticasone Propionate Pressurized Metered Dose Inhaler Formulation with Conventional and Anti-Static Plastic Valved Holding Chambers

D. von Hellen1, L. Slator2, R.H.M. Hatby2 and K. Nikander1. 1Philips Respironics, Respironics New Jersey, Inc., Parippany, New Jersey, USA. 2Respironics Respiratory Drug Delivery (UK) Ltd, Chichester, UK

Introduction

The dose emitted from the AC+ VHC was lower than the dose emitted from the anti-static VHCs.

Method

NGI), fine particle dose (amount of drug in NGI ≤ 4.7 μm), fine particle fraction (percentage of emitted dose in particles ≤ 4.7 μm) as in Figure 4, aerosol delivery from the pMDI alone is shown to be less efficient than from the pMDI VHC combinations for the delivery of drug to the lungs. That is, the proportion of the total aerosolized drug that would be expected to penetrate the upper airways and deposit in the conducting and alveolated airways is higher for the pMDI VHC combinations compared with the pMDI alone. [3]

Discussion

The fine particle dose from the pMDI alone and pMDI VHC combinations was similar, but the emitted dose was higher for the pMDI alone, meaning a greater amount of drug was delivered in larger particles that would be expected to deposit in the throat and upper airways. [11] The aerosol delivery characteristics from the three pMDI VHC combinations were comparable.

Conclusions

- The aerosol delivery characteristics were similar from the anti-static VHCs.
- The fine particle fraction was higher using a pMDI VHC combination than the pMDI alone due to the fact that the VHC acts as a filter for large particles, which could reduce the oropharyngeal deposition in patients using a pMDI.
- The MMAD of aerosols from each VHC was similar.

References


Acknowledgements: Drafting and editorial assistance was provided by L. Pearce and N. Smith of PS5 Consultants Ltd.

Presented at the 18th Congress of International Society for Aerosols in Medicine, 18th - 22nd June 2011, Rotterdam, The Netherlands.

Figure 1. The OptiChamber Diamond VHC can be used to optimize delivery from pMDIs. The valved holding chamber (VHC) has been designed to help improve and optimize delivery for those using pressurized metered dose inhalers (pMDIs). 1 The OptiChamber Diamond VHC (Diamond Philips Respironics, Respironics New Jersey, Inc., Parippany, NJ) is a compact, anti-static VHC designed to facilitate effective aerosol delivery to respiratory patients. The in vitro aerosol characteristics of an HFA fluticasone propionate pMDI with a preproduction Diamond VHC were compared with those of the pMDI with an AeroChamber Plus Z-Stat (Z-stat, Monaghan Medical Corp., Plattsburgh, NY) VHC, an AeroChamber Plus (AC+, Monaghan Medical Corp.) VHC and the pMDI alone.

Figure 2. Experimental test method. After each test the induction port, back-up filter, NGI cups and VHCs were processed using HPLC assay diluent. CITOAS V5.10 software was used to generate the aerosol characteristics data. The mean emitted dose (drug entering the NGI) leak tested and dried after each drug/VHC test.

Figure 3. Emitted dose (drug entering the NGI) from the pMDI alone, pMDI with Diamond VHC, pMDI with Z-Stat VHC and pMDI with AC+ VHC with the fine particle dose highlighted in the inset and the dose in particles > 4.7 μm highlighted. Error bars denote standard deviation about the mean.

Figure 4. Fine particle fraction (percentage of the emitted dose in particles ≤ 4.7 μm) from the pMDI alone, pMDI with Diamond VHC, pMDI with Z-Stat VHC and pMDI with AC+ VHC. Error bars denote standard deviation about the mean.

Figure 5. Mass Median Aerodynamic Diameter of the aerosol from the pMDI alone, pMDI with Diamond VHC, pMDI with Z-Stat VHC and pMDI with AC+ VHC. Error bars denote standard deviation about the mean.